Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Branched-chain amino acid supplementation impairs insulin sensitivity and promotes lipogenesis during exercise in diet-induced obese mice.
Zhang H, Xiang L, Huo M, Wu Y, Yu M, Lau CW, Tian D, Gou L, Huang Y, Luo JY, Wang L, Song W, Huang J, Cai Z, Chen S, Tian XY, Huang Y. Zhang H, et al. Among authors: tian d, tian xy. Obesity (Silver Spring). 2022 Jun;30(6):1205-1218. doi: 10.1002/oby.23394. Epub 2022 Mar 31. Obesity (Silver Spring). 2022. PMID: 35357085
Diurnal Fluctuations in Plasma Hydrogen Sulfide of the Mice.
Jin S, Tan B, Teng X, Meng R, Jiao X, Tian D, Xiao L, Xue H, Guo Q, Duan X, Wu Y. Jin S, et al. Among authors: tian d. Front Pharmacol. 2017 Oct 6;8:682. doi: 10.3389/fphar.2017.00682. eCollection 2017. Front Pharmacol. 2017. PMID: 29056911 Free PMC article.
Estimated Brain Age in Healthy Aging and Across Multiple Neurological Disorders.
Chai L, Sun J, Zhuo Z, Wei R, Xu X, Duan Y, Tian D, Bai Y, Zhang N, Li H, Li Y, Li Y, Zhou F, Xu J, Cole JH, Barkhof F, Zhang J, Zheng H, Liu Y. Chai L, et al. Among authors: tian d. J Magn Reson Imaging. 2024 Nov 26. doi: 10.1002/jmri.29667. Online ahead of print. J Magn Reson Imaging. 2024. PMID: 39588683
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762-8. Online ahead of print. Lancet. 2024. PMID: 39581202
3,258 results